Veradermics, Incorporated
New York Stock ExchangeTotal Valuation
Veradermics, Incorporated carries a market capitalization of 5.36B, placing it among publicly traded companies globally. Its enterprise value stands at 4.32B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5.36B |
| Enterprise Value | 4.32B |
Share Statistics
Veradermics, Incorporated currently has 41.78M shares outstanding.
| Shares Outstanding | 41.78M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 6.31 |
| P/TBV Ratio | 6.31 |
| P/FCF Ratio | -51.42 |
| P/OCF Ratio | -51.40 |
Financial Position
Veradermics, Incorporated maintains a current ratio of 70.53, meaning it holds 70.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 70.53 |
| Quick Ratio | 70.25 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 0.00 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -76.22 |
| Return on Assets (ROA) | -132.40 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Veradermics, Incorporated's stock has gained approximately 240.10596% over the past 52 weeks. The 50-day moving average sits at 109.42, while the 200-day moving average is 91.58.
| Beta (5Y) | N/A |
| 52-Week Price Change | 240.10596% |
| 50-Day Moving Average | 109.42 |
| 200-Day Moving Average | 91.58 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -101.83M, while operating income came in at -101.83M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -101.83M |
| Pretax Income | -92.68M |
| Net Income | -92.68M |
| EBITDA | -101.83M |
| EBIT | -101.83M |
| Earnings Per Share (EPS) | -2.83 |
Balance Sheet
Veradermics, Incorporated holds 819.89M in cash and equivalents against 428,000.00 in total debt, resulting in a net debt position of -319.33M. Total book value stands at 813.61M, with working capital of 813.05M providing operational flexibility.
| Cash & Cash Equivalents | 819.89M |
| Total Debt | 428,000.00 |
| Net Debt | -319.33M |
| Equity (Book Value) | 813.61M |
| Book Value Per Share | 19.47 |
| Working Capital | 813.05M |
Cash Flow
Veradermics, Incorporated produced -78.30M in operating cash flow over the past twelve months. After subtracting -26,000.00 in capital expenditures, free cash flow totaled -78.33M - equivalent to -2.39 per share.
| Operating Cash Flow | -78.30M |
| Capital Expenditures | -26,000.00 |
| Free Cash Flow | -78.33M |
| FCF Per Share | -2.39 |
Dividends & Yields
The company's payout ratio of 11.13 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | 11.13 |
| Shareholder Yield | -16.79 |
| FCF Yield | -1.94 |
Scores
Veradermics, Incorporated posts an Altman Z-Score of 254.72, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 254.72 |